Compare KODK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | LBRX |
|---|---|---|
| Founded | 1880 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.4M | 602.6M |
| IPO Year | 1994 | N/A |
| Metric | KODK | LBRX |
|---|---|---|
| Price | $7.55 | $24.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | ★ 603.2K | 145.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,114,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $13.40 |
| 52 Week High | $9.96 | $24.95 |
| Indicator | KODK | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 58.41 |
| Support Level | $6.24 | $22.48 |
| Resistance Level | $7.88 | $24.70 |
| Average True Range (ATR) | 0.29 | 1.32 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 51.32 | 84.65 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.